Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | £12,300 | £11,714 | £11,341 | £10,987 |
| % Growth | 5% | 3.3% | 3.2% | – |
| Cost of Goods Sold | £6,729 | £6,306 | £6,310 | £6,184 |
| Gross Profit | £5,570 | £5,408 | £5,031 | £4,803 |
| % Margin | 45.3% | 46.2% | 44.4% | 43.7% |
| R&D Expenses | £0 | £0 | £360 | £0 |
| G&A Expenses | £384 | £304 | £324 | £333 |
| SG&A Expenses | £3,046 | £2,845 | £2,876 | £2,826 |
| Sales & Mktg Exp. | £2,662 | £2,541 | £2,552 | £2,493 |
| Other Operating Expenses | £0 | £0 | -£360 | £0 |
| Operating Expenses | £3,046 | £2,845 | £2,876 | £2,826 |
| Operating Income | £2,525 | £2,563 | £2,155 | £1,977 |
| % Margin | 20.5% | 21.9% | 19% | 18% |
| Other Income/Exp. Net | -£127 | -£369 | -£248 | -£261 |
| Pre-Tax Income | £2,397 | £2,194 | £1,908 | £1,716 |
| Tax Expense | £554 | £502 | £416 | £349 |
| Net Income | £1,830 | £1,681 | £1,479 | £1,365 |
| % Margin | 14.9% | 14.3% | 13% | 12.4% |
| EPS | 4.1 | 3.77 | 3.31 | 3.06 |
| % Growth | 8.8% | 13.9% | 8.2% | – |
| EPS Diluted | 4.1 | 3.77 | 3.31 | 3.06 |
| Weighted Avg Shares Out | 446 | 446 | 446 | 446 |
| Weighted Avg Shares Out Dil | 446 | 446 | 446 | 446 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £210 | £278 | £299 | £289 |
| Depreciation & Amortization | £506 | £500 | £203 | £496 |
| EBITDA | £2,607 | £2,953 | £2,261 | £2,386 |
| % Margin | 21.2% | 25.2% | 19.9% | 21.7% |